Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze 6491 晶碩. Please read: https://finlab.finance/en/setup?stock=6491

No install, open FinLab Studio

6491

晶碩 Biotech & Healthcare As of 2026-06-17 Updated daily after market close

strong quality, fair valuation.

2 active signals
Revenue ≥20% Foreign buy
This page refreshes daily after the close. Add 晶碩 to your watchlist to track signal changes on your next visit.
Valuation 60Quality 85Growth 78Momentum 53Chips 98

Is 晶碩 a buy? Fundamentals and valuation first

  • Top-tier profitability.Operating margin beats ~92% of the market. Latest quarterly ROE ≈ 4.2%.

  • Valuation is neutral.PE is in the 26th market percentile; within its own history, PE is around the 20th percentile.

  • Foreign investors are net buying.Foreign 20-day net flow ≈ 25.3% of volume (net buy).

  • Strong revenue growth.Latest monthly revenue YoY ≈ 36.7%, above the 20% growth threshold.

  • Signals are active now.On the latest data, signals such as Revenue YoY ≥ 20%, Foreign net buying 5 straight days are active — see the historical forward returns after each occurrence below.

Chip flow

Bearish -0.25
BearishNeutralBullish

Distribution to retail — bearish

  • Distribution to retail — bearish
  • 美商高盛 holds 1,391 lots
  • sellers have 145 lots left, ~57 sessions to clear

Window from 2026-01-17 · Price +10% · branches to 2026-06-17· TDCC to 2026-06-12

  • Largest holder 美商高盛 has accumulated 1,391 lots since the start (sold 0%), still adding.
  • Main distributor 香港上海匯豐 peaked at 124 lots, has sold 44%, 69 left, ~15 sessions to clear at the recent pace.
  • TDCC big holders (absolute) >1000-lot holders -4.88pp, mid holders +3, retail +1.56pp — drifting down to retail.
  • Foreign hedge-desk net short Net short -49 lots (inferred from branch profile, mostly hedging — not necessarily bearish, not case-confirmed).
Branch inventory reconstruction
Accumulating holders Branches that accumulated shares during the window and still hold positive inventory; they are the absorbing side.
Distributing sellers Branches that built inventory earlier and have been selling it down; the remaining number estimates what has not cleared.
Net-short desks Trading-desk branches with negative inventory or net selling, often hedge, offsetting, or short-term flow. It is not automatically a bearish view.
Accumulating
美商高盛富邦-中壢凱基-台北摩根大通新加坡商瑞銀台灣摩根士丹利
Distributing
香港上海匯豐玉山證券玉山-雙和永豐金-羅東(牛牛牛)亞-鑫豐台新證券
Desks
own scale
元大證券福邦證券大和國泰永豐金證券
Price Accumulating & Distributing share one scale (comparable); Desks is independent. Zero is the baseline
Branch details Unit: lots

Accumulating

  • 美商高盛 +1,391
    sold 0%· still adding
  • 富邦-中壢 +1,194
    sold 1%
  • 凱基-台北 +588
    sold 0%· still adding
  • 摩根大通 +347
    sold 19%· still adding
  • 新加坡商瑞銀 +339
    sold 19%· still adding
  • 台灣摩根士丹利 +339
    sold 0%· still adding

Distributing

  • 香港上海匯豐 69 left
    sold 44%· ~15 sessions to clear
  • 玉山證券 64 left
    sold 26%· paused recently
  • 玉山-雙和 15 left
    sold 77%· paused recently
  • 永豐金-羅東 20 left
    sold 66%· paused recently
  • (牛牛牛)亞-鑫豐 17 left
    sold 70%· ~57 sessions to clear
  • 台新證券 23 left
    sold 58%· paused recently

Desks

  • 元大證券 -665
    unclassified
  • 福邦證券 -577
    unclassified
  • 大和國泰 -569
    hedge desk · will cover
  • 永豐金證券 -475
    unclassified
Still selling 145 lots ~57 sessions to bottom at most
Recent buy/sell force +1,890 absorbed / -118 sold buyers slightly ahead
TDCC big holders · absolute-holding cross-check
>1000-lot holder share Retail (<400 lots) share Price (right axis)

Weak direction: big-holder share fell while retail share rose.

Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.

Historical evidence

Signals active now

These signals are true on the latest data, with this stock's own historical forward-return stats after each occurrence.

Monthly revenue YoY ≥ 20% (from filing deadline)

Active · now 36.7%

Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).

67 historical occurrences (since 2019-10-07)
Average forward return after Monthly revenue YoY ≥ 20% (from filing deadline)。20-day: Win 61.5%, Sample 26, Median +3.47%, Excess +2.48%, Beat mkt rate 46.2%；60-day: Win 61.5%, Sample 26, Median +5.05%, Excess +3.95%, Beat mkt rate 46.2%；120-day: Win 60%, Sample 25, Median +12.84%, Excess +13.71%, Beat mkt rate 52%

120 days after: historical avg +22.45%

20-day +4.53%
60-day +9.59%
120-day +22.45%
20-day
60-day
120-day
Win
61.5%
61.5%
60%
Sample
26
26
25
Median
+3.47%
+5.05%
+12.84%
Excess
+2.48%
+3.95%
+13.71%
Beat mkt rate
46.2%
46.2%
52%

Over 25 occurrences, 120-day forward avg gained 22.45%, beat the market by 13.71 pts; win rate 60%.

Foreign net buying for 5 straight days

Active · now 10%

Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.

30 historical occurrences (since 2019-11-15)
Average forward return after Foreign net buying for 5 straight days。20-day: Win 56.7%, Sample 30, Median +2.42%, Excess -1.9%, Beat mkt rate 40%；60-day: Win 46.4%, Sample 28, Median -1.32%, Excess -3.22%, Beat mkt rate 35.7%；120-day: Win 48.1%, Sample 27, Median -5.22%, Excess -2.65%, Beat mkt rate 29.6%

120 days after: historical avg +13.38%

20-day +1.92%
60-day +6.08%
120-day +13.38%
20-day
60-day
120-day
Win
56.7%
46.4%
48.1%
Sample
30
28
27
Median
+2.42%
-1.32%
-5.22%
Excess
-1.9%
-3.22%
-2.65%
Beat mkt rate
40%
35.7%
29.6%

Over 27 occurrences, 120-day forward avg gained 13.38%, lagged the market by 2.65 pts; win rate 48.1%.

Valuation regime and subsequent returns

Each day's PE is converted to its own-history percentile (as of that day), then we look at adjusted-close returns over the next 240 trading days by valuation regime.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 You are here409+1.5% -1.4% 48.7% -39.1%
20-40 121-9.4% -5.6% 18.2% -31.8%
40-60 102-18.2% -16.1% 0% -34.9%
60-80 6Insufficient data
80-100 0Insufficient data

Percentiles use an expanding own-history window (no look-ahead); forward return is 240 trading days on adjusted close. Sample days overlap; distribution is indicative only.

Current PE ≈ 14.98, at the 20.0th percentile of its own history (0-20 band).

Valuation × momentum historical grid

Every day in its own history is bucketed by valuation tercile (own-history PE) and 60-day momentum sign into six cells; we show adjusted-close returns over the next 120 trading days per cell.

Valuation
Momentum
Cheap (own-history bottom 1/3)
Mid
Expensive (own-history top 1/3)
60-day momentum up
Now
-2%
Win rate 30.3% Excess -24.1%
188d
-6.9%
Win rate 30.1% Excess -23%
143d
Insufficient data
(0d)
60-day momentum down
-2.3%
Win rate 33.8% Excess -17.4%
411d
Insufficient data
(16d)
Insufficient data
(0d)

Currently in “Cheap (own-history bottom 1/3) × 60-day momentum up”: across 188 historical days, 120-day forward avg declined 2%, win rate 30.3%, lagged the market by 24.1%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Does this signal hold up across the market

Over the past 242 months, on average ~404 stocks per month met “monthly revenue YoY ≥ 20%”; their adjusted-close return over the next 60 trading days averaged 6.94% (equal-weighted), beating the market by 2.37 points on average, and outperformed the TAIEX total-return index in 64.5% of months.

Each month, equal-weighted 60-day forward adjusted return of all signal-matching stocks, then averaged across months; excess vs the TAIEX total-return index.

Signals not active (historical stats for reference)

These are not occurring now; historical samples shown for comparison.

252-day price high (breakout)

Pending

Adjusted close makes a new 252-day high; repeats within 20 days counted once.

What does 晶碩 do? Company profile

生技醫療業／醫療器材／軟式隱形眼鏡 上市（台灣證券交易所）

Overview

6491 為晶碩光學股份有限公司普通股，非 ETF、ETN、特別股或權證。公司成立於 2009-08-26，2019-10-07 於台灣證券交易所上市，總部及主要通訊地址位於桃園市龜山區興業街5號2樓之1，統一編號 25021158。董事長為郭明棟，總經理為楊德勝。依 TWSE 上市公司資料，實收資本額為新台幣 780,000,000 元，已發行普通股 78,000,000 股，每股面額新台幣 10 元。公司官網說明其由和碩聯合科技及景碩科技共同轉投資成立，主要從事軟式隱形眼鏡設計、研發、製造與銷售。依公司官網主要股東頁，2026-03-22 前十大主要股東包括景碩投資 27.22%、華毓投資 8.17%、華旭投資 6.33%、富邦人壽 4.27%、景碩科技 2.33%、南山人壽 2.00%、郭明棟 1.64%、新制勞工退休基金 1.53%、騰耀投資 1.42%、童子賢 1.41%。員工規模方面，2025 年年報揭露公司本體截至 2025-12-31 共有 1,859 名員工，不含子公司；2025 年平均員工人數為 1,776 人。

Business

晶碩為專業軟式隱形眼鏡製造廠，承接國內外品牌客戶代工，並提供產品設計、共同開發、代理銷售等相關服務。主要產品為拋棄式軟性隱形眼鏡，用於矯正近視、遠視、散光、老花等視力缺陷，也涵蓋彩色美妝、矽水膠高透氧、玻尿酸保濕、維他命成分、抗藍光、多焦、散光、近視控制等功能型產品。產品週期包括日拋、週拋、雙週拋、月拋、季拋與年拋；材質包括 HEMA-Base 水膠及 SiHy-Base 矽水膠。2025 年合併營收為新台幣 70.39409 億元，其中隱形眼鏡及相關收入 69.68607 億元、占 98.99%，其他收入 0.70802 億元、占 1.01%；內銷占 14%、外銷占 86%。商業模式以 ODM/OEM 代工、共同開發及多國產品證照布局服務全球品牌客戶為核心，同時公司過去亦經營自有品牌與通路。公司競爭利基包括原料配方、光學設計、藥液調配、自動化設備、自動化生產管理、少量多樣快速交貨、多國醫療器材品質系統與產品證照。2025 年年報揭露最大銷貨客戶 A 客戶占 22.41%，B 客戶占 11.03%，其餘客戶占 66.56%，客戶名稱未公開。

Outlook 2025–2028

2025 年營運基準：公司 2025 年合併營收創高至新台幣 70.39409 億元，年增 3.3%，但毛利率降至 52%，歸母淨利新台幣 16.2804 億元、年減 11%，主要原因包含市場價格競爭影響毛利率；營收成長主要受惠日本代工業務。2026 年公司在股東會年報中預期營收將高於 2025 年，並將持續領先台灣同業；2025 年於台灣大溪與中國大陸南通正式量產，江蘇海安廠後段水化與包裝線於 2025 年底投產，初期月產能約 450 萬片；台灣新廠完工後預計可增加 4,600 萬片產能；越南興安省產能布局可分散單一市場、生產與關稅風險。2026 至 2028 年主要成長動能包括日本市場、歐洲高階光學證照、矽水膠滲透率提升、日拋需求、功能性鏡片、彩片少量多樣需求、近視人口增加與全球品牌客戶外包。公司 2025 年研發費用新台幣 6.24683 億元，占營收 8.87%，2026 年預計投入超過新台幣 6.1 億元，方向包含高保濕矽水膠月拋彩妝鏡片、多彩對比設計、全時潤護保存液、近視控制散光三合一鏡片、多功能智慧隱形眼鏡、材料配方、表面塗層、封裝滅菌與自動檢測。中長期產業趨勢為全球軟式隱形眼鏡市場長期年成長約 4% 至 6%，矽水膠、日拋、功能型與美妝鏡片需求提升；風險包含中國市場價格競爭、全球前四大品牌廠規模與品牌優勢、醫療器材法規與取證時程、匯率波動、關稅與地緣政治、碳費與減碳要求、水電等製造成本、產品品質與召回風險、客戶集中度、產能擴充爬坡與新廠利用率不確定性。

Supply Chain

Upstream
  • HEMA 與其他甲基丙烯基親水性原料供應商 軟式隱形眼鏡鏡片本身主要原料；年報揭露供應商以甲、乙等代號呈現，未公開實際公司名稱。
  • 矽原料供應商 矽水膠 SiHy-Base 高透氧鏡片材料來源；實際供應商名稱未揭露。
  • 聚丙烯塑膠料與光學模具材料供應商 用於鏡片成形模具、上下蓋射出等製程；實際供應商名稱未揭露。
  • 功能性材料、油墨與保存液原料供應商 支援彩色鏡片、保濕、維他命、抗藍光與功能型鏡片；實際供應商名稱未揭露。
  • 鋁箔與各式包材供應商 用於封裝、滅菌後包裝與出貨；實際供應商名稱未揭露。
  • 景碩科技股份有限公司 3189 上市櫃公司；晶碩原始轉投資與主要股東相關方之一，並非年報明確揭露之原料供應商，列入上游/股東關係需視為關係企業背景。
  • 和碩聯合科技股份有限公司 4938 上市櫃公司；公司官網揭露晶碩由和碩聯合科技及景碩科技共同轉投資成立，屬關係企業背景，非年報明確揭露之直接供應商。
Downstream
  • 國內外品牌客戶 主要代工客戶；品牌商持有隱形眼鏡品牌並委託晶碩生產，年報揭露 A 客戶、B 客戶但未公開名稱。
  • 日本品牌與製販業者 日本為全球第二大隱形眼鏡市場且日拋需求高；晶碩持有日本相關產品證照並與日本客戶共同研發新品，實際客戶名稱未揭露。
  • 中國高端品牌客戶 公司年報提及中國市場價格競爭嚴峻，晶碩以產品品質、高階功能產品與穩定交期協助高端品牌客戶；實際客戶名稱未揭露。
  • 眼鏡行、藥妝店、超市與量販通路 產業下游終端通路，接觸最終隱形眼鏡使用者；多數為通路型態而非單一上市櫃公司。
  • 最終消費者與視光需求族群 終端應用包含近視、遠視、散光、老花、彩妝、抗藍光、保濕、矽水膠與功能性鏡片需求。

Competitors

  • 精華光學股份有限公司 1565 台股上櫃公司；台灣隱形眼鏡製造同業，年報列為台灣廠商競爭者之一。
  • 視陽光學股份有限公司 6782 台股上市櫃公司；台灣隱形眼鏡製造同業，年報列為台灣廠商競爭者之一。
  • 望隼科技股份有限公司 4771 台股上市櫃公司；台灣隱形眼鏡製造同業，年報列為台灣廠商競爭者之一。
  • 嬌生 國際大型隱形眼鏡品牌商；年報列為全球前四大隱形眼鏡製造商之一，母公司 Johnson & Johnson 為美國上市公司，非台股。
  • 酷柏 國際大型隱形眼鏡品牌商；年報列為全球前四大隱形眼鏡製造商之一，The Cooper Companies 為美國上市公司，非台股。
  • 愛爾康 國際大型隱形眼鏡與眼科公司；年報列為全球前四大隱形眼鏡製造商之一，Alcon 為海外上市公司，非台股。
  • 博士倫 國際大型隱形眼鏡與眼科公司；年報列為全球前四大隱形眼鏡製造商之一，Bausch + Lomb 為海外上市公司，非台股。
Sources（9）

This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.

Method and limitations

  • All returns use adjusted close (etl:adj_close), already adjusted for dividends and splits.
  • Excess return is measured against the TAIEX total-return index (dividends included).
  • Valuation regime and percentile stats use an expanding own-history window (no future data).
  • Revenue-signal event dates align to the first trading day after the filing deadline, avoiding look-ahead.
  • Event samples may overlap in time; stats describe historical distribution only and are less reliable when samples are few.

This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.